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Abstract
Astrocytes play several critical roles in the normal functioning of the mammalian brain, including ion homeosta-
sis, synapse formation, and synaptic plasticity. Following injury and infection or in the setting of neurodegener-
ation, astrocytes become hypertrophic and reactive, a process termed astrogliosis. Although acute reactive
gliosis is beneficial in limiting further tissue damage, chronic gliosis becomes detrimental for neuronal recovery
and regeneration. Several extracellular factors have been identified that generate reactive astrocytes; however,
very little is known about the cell-autonomous transcriptional mechanisms that regulate the maintenance of
astrocytes in the normal non-reactive state. Here, we show that conditional deletion of the stimulus-dependent
transcription factor, serum response factor (SRF) in astrocytes (SrfGFAPCKO) results in astrogliosis marked by
hypertrophic morphology and increased expression of GFAP, vimentin, and nestin. These reactive astrocytes
were not restricted to any specific brain region and were seen in both white and gray matter in the entire
brain. This astrogliosis persisted throughout adulthood concomitant with microglial activation. Importantly, the
Srf mutant mouse brain did not exhibit any cell death or blood brain barrier (BBB) deficits suggesting that apo-
ptosis and leaky BBB are not the causes for the reactive phenotype. The mutant astrocytes expressed more
A2 reactive astrocyte marker genes and the SrfGFAPCKO mice exhibited normal neuronal numbers indicating
that SRF-deficient gliosis astrocytes are not neurotoxic. Together, our findings suggest that SRF plays a criti-
cal role in astrocytes to maintain them in a non-reactive state.
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Significance Statement
In response to CNS injury, infection and in neurodegeneration, astrocytes undergo complex structural and
physiological changes termed as reactive gliosis. Currently, the molecular mechanisms that regulate the
non-reactive state of the astrocytes are poorly understood. We report that the serum response factor (SRF)
transcription factor is required for the maintenance of astrocytes in the non-reactive state such that its con-
ditional deletion in astrocytes results in widespread reactive astrogliosis. The SRF-deficient reactive astro-
cytes are persistent, non-proliferating and are not caused by cell death or impaired blood brain barrier
(BBB) integrity. In this regard, SRF regulates reactive astrocyte generation in the mammalian brain in a cell-
autonomous manner.
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Introduction
As an essential part of the CNS, astrocytes play critical
roles in nearly every facet of its development and function
including ion and neurotransmitter homeostasis, mainte-
nance of the blood brain barrier (BBB), synapse formation
and elimination, and synaptic transmission (Barres, 2008;
Kimelberg, 2010; Kimelberg and Nedergaard, 2010). In
addition, astrocytic dysfunction are central in several CNS
disorders such as epilepsy, amyotrophic lateral sclerosis
and Alzheimer’s disease (Seifert et al., 2006; Phatnani and
Maniatis, 2015). In response to CNS injuries and patholo-
gies, astrocytes undergo a spectrum of gene expression
as well as physiological and structural changes, a process
known as reactive astrogliosis (Burda and Sofroniew,
2014; Liddelow and Barres, 2017). These astrocytic re-
sponses depend on the severity of the CNS trauma and
can range from transient responses lasting a few days to
a more permanent glial scar formation (Sofroniew, 2009,
2015).
Reactive astrogliosis is largely considered beneficial to
the CNS, where reactive astrocytes provide protection by
several mechanisms, ranging from efficient uptake of exci-
totoxic glutamate, preventing oxidative stress and reduc-
ing edema, to restricting inflammation, facilitating BBB
repair and restricting spread of infection (Escartin and
Bonvento, 2008; Hamby and Sofroniew, 2010; Pekny and
Pekna, 2014). However, astrogliosis can also cause detri-
mental effects wherein reactive astrocytes inhibit CNS re-
generative responses, contribute to neuroinflammation,
generate reactive oxygen species and cause cell death
(Pekny and Pekna, 2014; Sofroniew, 2014). Previous stud-
ies have identified several extracellular factors and intracel-
lular signaling pathways that regulate different aspects of
astrogliosis including cytokines, growth factors, purines,
endothelin-1, BMP receptors, Eph4, and Aquaporin 4
(Correa-Cerro and Mandell, 2007; Kang and Hébert, 2011;
Sofroniew, 2014).
Currently, we know little about the identities of tran-
scription factors that are necessary to maintain astrocytes
in a non-reactive state. Serum response factor (SRF) is a
stimulus-dependent transcription factor important for
several aspects of nervous system development (Knöll
and Nordheim, 2009). SRF has been shown to play a criti-
cal role in oligodendrocyte and astrocyte development
(Stritt et al., 2009; Lu and Ramanan, 2012) but its func-
tions in astrocytes remain unknown. In this study, we con-
ditionally ablated SRF in astrocytes using a GFAP-Cre
transgenic line (Bajenaru et al., 2002). The brains of
SrfGFAPCKO mice exhibited reactive astrogliosis starting
threeweeks of age. These reactive astrocytes were not
restricted to any specific region and were seen through-
out the brain. The reactive gliosis persisted throughout
adulthood with concomitant microglial activation. We did
not observe any changes in cell death or BBB integrity, in-
dicating that these extrinsic factors are unlikely the cause
of gliosis. Together, our findings suggest that SRF is a
critical cell-autonomous regulator of non-reactive state of
astrocytes throughout the brain.
Materials and Methods
Animals
The Srf-floxed mice were previously described
(Ramanan et al., 2005) These mice were bred with
hGFAP-Cre (generously provided by David Gutmann,
Washington University School of Medicine, St. Louis, MO)
to obtain Srff/f-GFAPCre1/ (SrfGFAPCKO). Srff/f mice
served as control in all experiments. Both male and
female mice were used in all the experiments. All ex-
periments were conducted in accordance with the ani-
mal care standards and use and approved by the
Institutional Animal Ethics Committee. Control and
mutant mice were housed together, and cage mates
were randomly assigned to experimental groups. All
experiments were conducted blinded to the genotype
of the mice used.
Immunohistochemistry
Mice were fixed by transcardial perfusion using 4% para-
formaldehyde (PFA). The brains were cryoprotected in 30%
sucrose, frozen and stored in 80°C until further use. For
staining, 30-mm-thick cryosections were incubated in block-
ing/permeabilization solution containing 0.3% Triton X-100
and 3% goat serum in PBS (pH 7.4) for 1 h followed by over-
night incubation in primary antibody. The brain sections
were then washed in PBS and incubated in secondary anti-
body for 1 h. The sections were finally mounted in DAPI-
containing mounting medium (Vector Laboratories). For SRF
immunostaining, heat-induced epitope retrieval was con-
ducted by incubating the sections in 10 mM sodium citrate,
pH 8.9 for 30min at 95°C. The following primary antibod-
ies were used: anti-GFAP (1:1000; Sigma-Aldrich catalog
#G3893, RRID:AB_477010), anti-GFAP (1:1000; Agilent
catalog #Z0334, RRID:AB_10013382), anti-Nestin (1:1000;
Millipore catalog #MAB5326, RRID:AB_2251134), anti-
Vimentin (1:50; DSHB catalog #40E-C, RRID:AB_528504),
anti-S100b (1:1000; Sigma-Aldrich catalog #S2644, RRID:
AB_477501), anti-S100b (1:500; Synaptic systems catalog
#287006, RRID:AB_2713986), anti-Aldh1L1 (1:100; UC
Davis/NIH NeuroMab Facility catalog #73-140, RRID:AB_
10673447), anti-Iba1 (1:1000; Wako catalog #019-19741,
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RRID:AB_839504), anti-phosphohistone H3 (phH3; 1:500;
Sigma-Aldrich catalog #H0412, RRID:AB_477043), anti-
caspase-3 active (1:1500, Millipore catalog #04-439, RRID:
AB_673061), anti-SRF (1:200; Santa Cruz Biotechnology
catalog #sc-335, RRID:AB_2255249), and anti-NeuN (1:500;
Millipore catalog #MAB377, RRID:AB_2298772). Secondary
antibodies were as following: Alexa Fluor 488-, 594-,
and 647-conjugated anti-rabbit, anti-chicken, and
anti-mouse at 1:1000 dilution (Life Technologies).
Biotinylated anti-mouse and anti-rabbit secondary
antibodies (1:250; Vector Laboratories) were used
along with Vectastain ABC Elite, ImmPACT VIP sub-
strate and ImmPACT DAB substrate kits (Vector Labs).
All the images were captured using conventional fluo-
rescence microscopy (Eclipse 80i, Nikon), except the
images for SRF immunostaining and BBB measure-
ment, which were captured using a confocal micro-
scope (LSM 880, Zeiss).
RNA isolation and quantitative real-time PCR
Total RNA was isolated from forebrain of three- to five-
week-old control and SrfGFAPCKO mice using the PureLink
RNA Mini kit (ThermoFisher Scientific) as per the manufac-
turer’s protocol; 2mg of total RNA was used for first-strand
cDNA synthesis using the first strand synthesis kit (Invitrogen
Inc.). Quantitative RT-PCR was done with 100ng of cDNA
and KAPA SYBR FAST ABI prism kit (catalog #KK4604)
using the following program: 95°C or 3min followed by 39
cycles of 95°C for 5 s, 55°C for 30 s and 72°C for 40 s. The
PCR reaction was conducted in QuantStudio 7 Flex Real-
Time PCR System (Invitrogen Biosciences). The primers
used were: Srf, forward (Fwd), 59-ACCAGTGTCTGCTAGT
GTCAGC-39 and reverse (Rev), 59-CATGGGGACTAGGGT
ACATCAT-39; Rps29, Fwd 59-CCAGCAGCTCTACTGG
AGTCA-39 and Rev, 59-AGACTAGCATGATCGGTTCCA-39.
Il1b , Fwd, 59-ATCAACAAGCAATTCCTCGATGA-39 and
Rev, 59-CAGCATTCGCTTCAAGGACATA-39; TNFa, Fwd,
59-CCCTCACACTCAGATCATCTTCT-39 and Rev, 59-GCTA
CGACGTGGGCTACAG-39; Ccl2, Fwd, 59-TTAAAAACCTG
GATCGGAACCAA-39 and Rev, 59-GCATTAGCTTCAGATTT
ACGGGT-39. Expression of Srf and other genes were nor-
malized to that of the housekeeping gene, Rps29. The pri-
mers for A1, A2, and pan-reactive astrocytes were from a
previously published study (Liddelow et al., 2017).
BBB permeability assay
Two assays were used as previously described
(Andreone et al., 2017) to measure the integrity of BBB
using 6-mon old SrfGFAPCKO mice. In the first assay,
mice were deeply anesthetized with isoflurane and in-
jected with 20 ml of 10-kDa dextran fluorescein (10mg/
ml, Invitrogen; D1820) into the left ventricle of the
heart, and allowed to circulate for 5min. Their brains
were collected and postfixed in 4% PFA overnight, fro-
zen and stored at 80°C; 30-mm-thick cryosections
were mounted using mounting media supplemented
with DAPI (Vector Labs) and analyzed using a confocal
microscope (LSM 880, Zeiss). In the second assay,
10 ml of HRP Type II (5 mg/ml) was administered
transcardially and allowed to circulate for 5min. The
brains were collected and immersed in 2% glutaralde-
hyde in 4% PFA in cacodylate buffer (0.1 M, pH 7.3) at
room temperature for 1 h. The brains were then shifted
to 4°C overnight and sectioned at 100 mm using a Leica
vibratome and processed using ImmPACT VIP kit
(Vector Labs). For quantification of dextran fluorescein
injection, epifluorescence images (63) of brain sec-
tions were analyzed using ImageJ. Brain sections from
the same rostro-caudal position were analyzed. At
least 12 different regions were taken and the ratio of
the fluorescence or color intensity (outside vs inside
the vessel) was measured.
Quantification of fluorescence intensity and cell
numbers
For measuring fluorescence intensity, images were
scaled for 10 magnification and normalized to the same
exposure time. Ten to 12 areas of field [region of interest
(ROI), 500 500 mm2] in the same rostro-caudal axis were
drawn per image, and the intensities were measured
using ImageJ (Fiji) after subtracting the background fluo-
rescence from both control and knock-out sections. For
the hippocampus, cell numbers or fluorescence inten-
sities were measured in the stratum oriens and stratum ra-
diatum. For cell counts, images were taken at 4
magnification. Four ROIs of 1200 1200 mm2 (1 mm2 for
hippocampal CA1 and CA3) in the same rostro-caudal
axis were drawn per image, and the number of cells per
ROI were counted with cell counter plugin using ImageJ
(Fiji). For SRF fluorescence intensity, the SRF fluores-
cence signal within the DAPI area was quantified using
ImageJ.
Quantification of microglial activation
Brain sections from SrfGFAPCKO mice and control lit-
termates at different ages (three weeks and three and
12 months) were fluorescently immunostained for Iba1.
At least five different cortical regions in the same ros-
tro-caudal axis were taken in all the mice to measure
fluorescence intensity. This was then compared be-
tween the control and the knock-out mice to get the
fold difference in fluorescence. ImageJ was used to
measure the percentage increase in fluorescence per
unit field and this was compared between control and
knock-out groups at all the experimental time points as
mentioned in statistical analysis. The area of the field
was 500 500 mm2.
Terminal deoxynucleotidyl transferase-mediated
biotinylated UTP nick end labeling (TUNEL) assay
The TUNEL assay was conducted using Click-IT Plus
TUNEL assay kit (Invitrogen, ThermoFisher Scientific) ac-
cording to the manufacturer’s instructions. Briefly, brains
fixed in 4% PFA and 30-mm cryosections were permeabil-
ized with proteinase K solution for 15min and then incu-
bated with TdT reaction mixture for 60min at 37°C and
subsequently with EdUTP for 30min. The detection was
achieved through click reaction between the dUTP bound
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Figure 1. Astrocyte-specific deletion of Srf in SrfGFAPCKO mice. A, Representative images of immunostaining for SRF (red), S100b
(green), and NeuN (blue) shows SRF expression in astrocytes (arrows) and neurons (arrowheads) in the cortex and striatum of con-
trol mice. SRF expression was seen only in the neurons but not in the astrocytes in SrfGFAPCKO mice mutant mice. A’,
Representative higher magnification images of astrocytes and neurons from A showing SRF expression in control astrocytes and
neurons and absent in mutant astrocytes. B, Quantification of SRF immunofluorescence in S100b1 astrocytes from A. At least 15–
20 cells per mouse were analyzed (n=3 mice). Astrocytes: cortex, control (16.496 2.52), SrfGFAPCKO (4.806 0.29); striatum, control
(19.726 3.179), SrfGFAPCKO (7.4061.47); neurons: cortex, control (24.336 5.05), SrfGFAPCKO, control (28.476 5.60); striatum, con-
trol (30.796 1.40), SrfGFAPCKO (23.416 3.09). C, Quantitative real-time PCR from whole-brain total RNA shows a significant de-
crease in Srf mRNA expression in the mutant mice relative to control mice; control (1.06 0), SrfGFAPCKO (0.306 0.14; n=3 mice).
D, Semi-quantitative PCR from whole-brain total RNA shows a significant decrease in Srf mRNA expression in the mutant mice.
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alkyne group and a picolyl azide fluorescent dye for
30min. The slides were washed with 3% BSA in PBS for
5min and rinsed in 1 PBS. The slides were mounted
using mounting medium containing DAPI (Vector Labs)
and observed using an epifluorescence microscope
(Eclipse 80i, Nikon) using appropriate filters and captured
using MetaMorph software. Numbers of TUNEL1 cells in
the CA1, CA3, and DG regions of entire rostral to caudal
brain regions were counted using ImageJ software. The
area of the field for counting the number of TUNEL1 cells
was 250 250 mm2.
Statistical analyses
Analyses were done using GraphPad Prism 6. The com-
parisons between two groups were done using unpaired
two-tailed Student’s t test. All the statistical details for
each experiment, including the n value, the statistical test
used, p value, significance of comparisons is mentioned
in the figure legends.
Results
Srf deletion in astrocytes results in reactive
astrogliosis
To study the function of SRF in astrocytes, we gener-
ated SrfGFAPCKO conditional knock-out mice using a
hGFAP-Cre transgenic mouse line, in which Cre expres-
sion was found to occur predominantly in astroglial pro-
genitor cells starting at embryonic day (E)16.5 (Bajenaru
et al., 2002). SrfGFAPCKO mice were obtained in normal
Mendelian ratio, appeared normal at birth, and did not ex-
hibit any gross morphologic deficits such as neocortical
lamination and hippocampal architecture (data not
shown). We first confirmed Srf deletion in astrocytes. Co-
immunostaining for SRF, S100b , and NeuN revealed
continued
Rps29 expression served as the loading control (n=3 mice). Control (1.046 0.01), SrfGFAPCKO (0.246 0.02; n=3 mice). Scale bars:
50 mm (A) and 20 mm (A’); *p, 0.05, **p, 0.005, ***p, 0.0005; ns, not significant. Two tailed t test. Data are mean 6 SEM.
Figure 2. Conditional deletion of SRF in astrocytes results in reactive gliosis. A, Representative images of immunostaining for GFAP
and ALDH1L1 in three-week-old SrfGFAPCKO and control littermates shows higher expression of these markers in neocortex (Ctx)
and hippocampus (Hc) of mutant mice as compared with control littermates. B, C, GFAP and S100b immunostaining also showed
that the astrocytes in mutant mice were hypertrophic compared with control mice (n=3 mice). D, Quantification of S100b1 astro-
cytes from (C). Cortex, control (76.586 1.19), SrfGFAPCKO (50.256 5.67); striatum, control (70.716 3.61), SrfGFAPCKO
(66.046 3.72); hippocampus, control (11.9060.17), SrfGFAPCKO (10.886 1.14; n=3 mice). Scale bars: 100 mm (A) and 50mm (B, C);
ns, not significant. Two tailed t test. Data are mean 6 SEM.
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Figure 3. SRF ablation in astrocytes leads to widespread astrogliosis. A, Representative images of immunostaining for the astroglio-
sis marker, nestin in three-week-old SrfGFAPCKO and control littermates shows reactive astrocytes in cortex and hippocampus of
Srf mutant mice but not in control littermates. B, Quantification of nestin fluorescence intensity shown in A. Cortex: control
(0.06 0.14), SrfGFAPCKO (771.96 16.14), hippocampus: control (0.06 8.15), SrfGFAPCKO (556.16 38.56; n=3 mice). C,
Representative images showing co-immunostaining with GFAP and the gliosis marker, vimentin. There is little or no GFAP and vi-
mentin expression in three-week control mice. In contrast, the astrocytes in mutant mice exhibit strong expression and
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robust SRF expression in both the astrocytes and neurons
in three- to five-week-old control mice (Fig. 1A). In the
brain sections of SrfGFAPCKO mutant mice, there was ro-
bust SRF expression in neurons while it was absent in the
astrocytes (Fig. 1A,B). We observed that the antigen re-
trieval method caused a slightly punctate SRF immuno-
staining, which was more pronounced in the mutant
sections. However, this pattern of staining overlapped
with NeuN but not with S100b in the mutant sections
(Fig. 1A). Quantitative and semi-quantitative real-time
PCR using total RNA isolated from whole brain showed
decreased Srf expression in mutants relative to controls
(Fig. 1C,D).
We then asked whether Srf deletion had any effect on
astrocyte development. In three- to five-week-old control
mice, astrocytes in hippocampus and fibrous astrocytes
in the white matter expressed GFAP, while there was no
detectable GFAP expression in the neocortical astro-
cytes, which have been shown to downregulate GFAP ex-
pression postnatally (Buffo et al., 2008; Robel et al., 2009;
Fig. 2A,B). However, the astrocytes in control mice ex-
pressed other astrocytic markers, such as S100b (Fig.
2C). In striking contrast, astrocytes in the SrfGFAPCKO
mice exhibited pronounced GFAP expression (Fig. 2A,B)
along with hypertrophic morphology as seen from immu-
nostaining for GFAP, Aldh1L1, and S100b (Fig. 2A–C),
both hallmarks of reactive astrogliosis. Cell counts of
S100b1 cells revealed no change in the number of astro-
cytes between control and mutant mice in all regions ana-
lyzed (Fig. 2D). We had shown earlier that neuron-specific
deletion of SRF does not affect astrocyte differentiation or
cause reactive gliosis (Lu and Ramanan, 2012). Therefore,
although unlikely, any transient Cre expression in neurons
by the hGFAP-Cre transgene is unlikely to cause the glio-
sis phenotype seen in SrfGFAPCKOmice.
Astrocytes exhibit regional heterogeneity and previous
gene deletion studies have shown region-specific genera-
tion of reactive astrocytes (Garcia et al., 2010; Kang et al.,
2014). We therefore asked whether reactive astrocytes in
SrfGFAPCKO mice were also regionally restricted. For this,
we analyzed serial sections from the entire brain of control
and Srf knock-out mice. We found that astrocytes in most
regions of the brain in control mice did not express or
weakly expressed GFAP (Fig. 2A,B). In striking contrast,
brain sections from SrfGFAPCKO mice exhibited intense
GFAP expression in all brain regions analyzed including
in striatum and corpus callosum (Fig. 2A,B). To further
confirm that the astrocytes in SrfGFAPCKO mice are in-
deed reactive, we immunostained for known astroglio-
sis markers, vimentin and nestin (Ridet et al., 1997). In
contrast to control littermates, the SrfGFAPCKO mice ex-
hibited robust nestin-positive (Fig. 3A,B) and vimentin-
positive (Fig. 3C,D) astrocytes, thus confirming their
reactive state. These observations suggest that astro-
cyte-specific deletion of Srf results in reactive
astrocytes.
Astrogliosis seen in Srf knock-out mice is not induced
by cell death
Astrogliosis is generally induced by several extrinsic
factors, such as cell death or a leaky BBB (Pekny and
Nilsson, 2005). We first analyzed cell death by immuno-
staining for cleaved caspase-3 as well as by TUNEL stain-
ing. We did not observe any discernible cell death at
twoweeks of age in SrfGFAPCKO mice, just before the
onset of astrogliosis (Fig. 4A–C). This strongly suggested
that reactive astrogliosis seen in the Srf knock-out mice is
not triggered by cell death. During conditions of severe
neural injury or trauma, reactive astrocyte undergo prolif-
eration (Sofroniew, 2014). To determine whether SRF-de-
ficient reactive astrocytes are proliferating, brain sections
from SrfGFAPCKO mice and control littermates were im-
munostained with the proliferation marker, phH3. There
were no phH3-positive cells observed in either Srf mutant
mice or their control littermates, excluding the presence
of proliferating astrocytes (Fig. 4D).
BBB is unaffected in Srf knock-out mice
Given the widespread and persistent reactive astroglio-
sis seen in Srfmutant mice, it is possible that a leaky BBB
could be the likely cause for the astrogliosis observed in
Srf knock-out mice (Pekny and Nilsson, 2005). To study
BBB integrity, we injected two different tracers, 10-kDa
dextran fluorescein (Fig. 5A–C) and 44-kDa HRP Type II
(Fig. 5A,D,E), into three- to five-week-old SrfGFAPCKO
mutant and control mice (Andreone et al., 2017). We did
not observe any discernible presence of these tracers in
the brain parenchyma of Srf knock-out mice relative to
their littermate controls (Fig. 5), supporting an intact BBB.
Persistent reactive astrogliosis seen in SrfGFAPCKO
mice throughout adulthood
Astrogliosis could be a transient phenomenon, lasting a
few days to several weeks, or a long-lasting event result-
ing in a glial scar, depending on the severity of trauma or
injury (Sofroniew, 2014). We therefore asked whether the
astrogliosis seen in SrfGFAPCKO mice is a transient pro-
cess. To address this, we immunostained brain sections
from three- and 12-month-old control and knock-out
mice. The astrocytes in hippocampus of control mice
showed normal GFAP expression while there was very
faint or no GFAP expression in the astrocytes in the other
brain regions both at either three (Fig. 6A,B) or 12 (Fig.
6C,D) months of age. In contrast, the astrocytes in the
continued
colocalization of GFAP and vimentin. D, Quantification of fluorescence intensity in C. For GFAP, cortex, control (102.16 5.28),
SrfGFAPCKO (580.16 62.10); hippocampus, control (228.0634.20), SrfGFAPCKO (638.16 73.97); striatum, control (85.786 1.83),
SrfGFAPCKO (256.96 7.73). For vimentin, cortex, control (2.936 0.99), SrfGFAPCKO (674.106 27.70); hippocampus, control
(12.026 12.02), SrfGFAPCKO (964.106 11.79); striatum, control (2.336 0.33), SrfGFAPCKO (633.506 41.37). Shown here are neocor-
tex, hippocampus (Hpc), and striatum (Str; n=3 mice). Scale bars: 500 mm (A) and 50 mm (C); **p, 0.005, ***p, 0.0005,
****p, 0.0001. Two tailed t test. Data are mean 6 SEM.
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Figure 4. Absence of cell death in Srf mutant mice. A, Representative images of TUNEL staining of two-week-old SrfGFAPCKO mice
and control littermates. Amplified view of boxed region is shown on right. Arrows show TUNEL1 cells while the arrowhead shows
non-specific staining. B, Representative images of immunostaining for cleaved caspase-3 in the neocortex and hippocampus of
two-week-old SrfGFAPCKO mice and control littermates. Amplified view of boxed region is shown on right. Arrows show cleaved
caspase 31 cells while the arrowhead shows non-specific staining. C, Quantification of TUNEL1 and cleaved caspase-31 cells in
neocortex and hippocampus (Hpc) shows the no significant difference in the number of dead cells between SrfGFAPCKO mice and
control littermates. Caspase-3: cortex, control (2.2061.00), SrfGFAPCKO (1.456 0.77); hippocampus, control (1.166 0.65),
SrfGFAPCKO (0.916 0.79). TUNEL: cortex, control (0.3760.21), SrfGFAPCKO (0.086 0.052); hippocampus, control (0.816 0.21),
SrfGFAPCKO (1.186 0.25; n=3 mice). D, Representative images of immunostaining for the proliferation marker, phH3 in three-week-
old SrfGFAPCKO and their respective control mice showed no proliferating cells in the mutant mice. Immunostaining of P0.5 mouse
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knock-out mice, at both three and 12months of age, ex-
pressed intense GFAP expression and exhibited hypertro-
phy in all brain regions (Fig. 6A–D) similar to that seen at
threeweeks (Figs. 2, 3). To further confirm astrogliosis,
we immunostained for vimentin and found robust expres-
sion only in the astrocytes in the knock-out mice but not in
their control littermates (Fig. 6E–G). Immunostaining for
phH3 did not reveal any positive cells, suggesting that these
astrocytes are also not proliferative in older mice (Fig. 6H).
Together, these observations demonstrate that SRF abla-
tion in astrocytes results in widespread astrogliosis that per-
sists through adulthood.
Microglial activation in SrfGFAPCKOmice
Reactive astrocytes are often observed along with mi-
crogliosis (Frank and Wolburg, 1996; Zhang et al., 2010).
We therefore asked whether microglia exhibited a reactive
state in the Srf knock-out mice. Immunostaining for the
microglial marker, Iba1 showed increased expression in
brain sections from three-week-old mutant mice, relative
to control littermates, indicative of reactive microglia (Fig.
7A,B). We then quantified the number of Iba11 cells and
found no significant difference in microglial numbers be-
tween control and knock-out mice (Fig. 7C). However,
we noticed that the microglia tend to form clusters in the
continued
brain section showed many phH3-positive cells and served as a control; n.s., not significant. Two-tailed t test. Data are mean 6
SEM. Scale bars: 20mm (A’, B’) and 200 mm (A, B) and 100 mm (D); n=3 mice.
Figure 5. BBB is not compromised in SrfGFAPCKO mice. A, Schematic diagram showing experimental timeline of dextran fluorescein
(DF) and HRP injection and tissue processing. B, 10-kDa TMR-dextran fluorescein (DF) tracer injection reveals normal architecture
of cerebral vasculature in three- to five-week-old SrfGFAPCKO and their control littermates. C, Quantification of ratio of fluorescence
intensity outside versus inside the blood vessel reveals no significant difference between SrfGFAPCKO mice and their control litter-
mates, indicative of intact BBB. A stab-wounded brain served as a control to show BBB leakage. Control (0.216 0.0), SrfGFAPCKO
(0.186 0.05), stab-wound (1.976 0.26; n=3 mice). D, Transcardial injection of 44-kDa HRP Type II in SrfGFAPCKO mice and their re-
spective controls shows that HRP was restricted to the blood vessel lumen. E, Quantification of ratio of color intensity outside ver-
sus inside the blood vessel shows no significant difference between control and mutant mice (n=3 mice). Control (0.166 0.05),
SrfGFAPCKO (0.206 0.02), stab-wound (1.456 0.08). Scale bars: 400 mm (B) and 200 mm (D); ns, not significant; ****p, 0.0001, one-
way ANOVA, data are mean 6 SD.
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Figure 6. Persistent astrogliosis in SrfGFAPCKO mice. A, Immunostaining for GFAP in three-month-old, (3-mon) SrfGFAPCKO mice
and control littermates shows widespread astrogliosis in all the brain regions. B, Quantification of color intensity in A. Cortex,
control (107.26 0.61), SrfGFAPCKO (176.46 7.35); hippocampus, (Hpc), control (270.26 9.11), SrfGFAPCKO (385.46 16.14);
striatum, control (151.46 1.280), SrfGFAPCKO (260.66 18.58; n = 3 mice). C, Representative images of immunostaining for
GFAP in 12-month-old, (12-mon) SrfGFAPCKO mice and control littermates shows persistent astrogliosis in all the brain regions
analyzed. Shown here are cortex, hippocampus (Hpc), and striatum. D, Quantification of relative color intensity in C.
Quantification of color intensity in C; cortex, control (188.26 2.85), SrfGFAPCKO (536.06 26.03); hippocampus, control
(356.36 6.89), SrfGFAPCKO (591.0629.43); striatum: control (191.16 4.83), SrfGFAPCKO (495.76 80.51; n = 3 mice). E,
Representative images of immunostaining for reactive astrogliosis marker, vimentin, in three- and 12-month-old SrfGFAPCKO
mice and control littermates shows gliosis astrocytes only in the brains of Srf mutant mice. F, G, Relative fluorescent intensity
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cortex and hippocampus (Fig. 7A). We next asked
whether microgliosis also persisted throughout adult-
hood similar to that seen for astrogliosis. As seen at
three weeks, brain sections from three- and 12-month-
old SrfGFAPCKO mice also showed strong upregulation
of IbaI expression relative to that from control mice
(Fig. 7D,E), suggesting that microglia also exhibited a
reactive state along with reactive astrocytes. Similar to
that seen at three weeks of age, we did not find any dif-
ference in the number of Iba11 cells in both three- and
12-month-old SrfGFAPCKO mice compared with con-
trol littermates (Fig. 7F,G). Immunostaining for prolifer-
ation marker, phH3 did not reveal any positive cells
(Figs. 4D, 6H), indicating that these reactive microglia
are also not proliferative.
Persistent gliosis in SrfGFAPCKOmice does not affect
neuronal viability
Recent studies have shown that reactive astrocytes can
be broadly classified as either neurotoxic (A1) or neuro-
protective (A2) depending on the external stimuli
(Zamanian et al., 2012; Liddelow et al., 2017). In order to
determine the phenotypic state of SRF-deficient reactive
astrocytes, we performed quantitative RT-PCR for some
of the A1 (Psmb8, H2T23, H2D1, Srgn), A2 (Cd109, Ptgs2,
Clcf1, Cd14), and pan-reactive marker genes (Serpina3n,
Gfap). Although we found that the SrfGFAPCKO mice ex-
pressed both A1 and A2 genes, there were more A2 reac-
tive astrocyte marker genes that were upregulated
compared with A1 genes suggesting that the SRF-defi-
cient reactive astrocytes are likely to be A2-like (Fig. 8A).
Since we also observed microgliosis, we next assessed
the expression of neuroinflammatory genes. Quantitative
PCR showed a significant increase in the expression of
Il1b and Ccl2/Mcp-1 but not TNFa in the brains of
SrfGFAPCKO mice (Fig. 8A), suggesting that these genes
could be one of the underlying causes of microgliosis ob-
served in the Srfmutant mice.
We next asked whether prolonged gliosis in the SRF-
GFAP mutant mice affected neuronal numbers. For this,
five-week-old and 12-month-old brain sections from
SrfGFAPCKO mice and control littermates were immuno-
stained for the neuronal marker, NeuN. We did not ob-
serve any significant difference in NeuN-positive cells in
the brains of mutant and control mice at both these
ages (Fig. 8B–D). This suggested that persistent gliosis
observed in the brains of SrfGFAPCKO mice did not af-
fect neuronal survival and that SRF-deficient reactive
astrocytes are likely not neurotoxic.
Discussion
Reactive astrogliosis is an important cellular response
to neuronal injury, infection and neurodegeneration in
the CNS, and this is critical to reduce inflammation, re-
strict tissue damage and cell death, and promote tissue
repair (Sofroniew, 2005; Pekny and Pekna, 2014).
Currently, very little is known about the cell-intrinsic
mechanisms that regulate the conversion of an astro-
cyte from a non-reactive to a reactive state. In this
study, we show that deletion of the transcription factor,
SRF in astrocytes results in widespread reactive gliosis
in the brain starting three weeks of age. The reactive as-
trocytes persisted along with microgliosis throughout
adulthood and both astrocytes and microglia did not
exhibit proliferation. Our results suggest that SRF is re-
quired in a cell-autonomous manner to regulate reactive
astrogliosis in the mammalian brain.
SRF is a ubiquitously expressed transcription factor
that has been shown to play critical roles in several as-
pects of nervous system development and function (Knöll
and Nordheim, 2009). Deletion of SRF in developing and
adult neurons resulted in deficits in neuronal migration,
axon growth, hippocampal circuit formation, activity-de-
pendent gene expression, and learning and memory
(Alberti et al., 2005; Ramanan et al., 2005; Etkin et al.,
2006; Knöll et al., 2006; Wickramasinghe et al., 2008;
Stritt and Knöll, 2010; Johnson et al., 2011; Lu and
Ramanan, 2011; Li et al., 2014). Deletion of SRF within
neural stem cells specifically affected differentiation to
both astrocytes and oligodendrocytes (Lu and Ramanan,
2012). Interestingly, neuronal SRF deletion did not affect
astrocyte differentiation or cause any reactive astrogliosis
(Lu and Ramanan, 2012) but revealed a paracrine effect of
neuronal SRF on oligodendrocyte maturation and myeli-
nation (Stritt et al., 2009; Anastasiadou et al., 2015).
Currently, the role of SRF in astrocyte development re-
mains poorly understood. This study identifies a critical
role for SRF in maintenance of astrocytes in a non-reac-
tive state. However, it is possible that since SRF deletion
in the SrfGFAPCKO mice likely starts around E16.5 during
embryonic development, the reactive astrogliosis could
be because of developmental deficits.
Previous studies have shown that genetic ablation of
the extracellular matrix protein, b 1-integrin (Itgb 1) in as-
trocytes results in astrogliosis starting fourweeks of age
and Itgb 1 mutant mice exhibit spontaneous seizures
(Robel et al., 2009, 2015). Attenuation of sonic hedgehog
(Shh) signaling in postnatal astrocytes resulted in reactive
astrocytes that were restricted to the forebrain alone sug-
gesting a role for Shh in maintaining the non-reactive
state of specific astrocytic populations (Garcia et al.,
2010). Similarly, attenuation of fibroblast growth factor
(FGF) signaling by deletion of FGF receptors, FGFR1–3,
resulted in astrogliosis that was restricted to the neocor-
tex and hippocampus although deletion occurred in other
regions as well (Kang et al., 2014). Interestingly,
continued
of vimentin immunostaining in three-month-old (F) and 12-month-old (G) mice compared with control littermates. F, Cortex, control
(11.526 11.52), SrfGFAPCKO (317.16 39.27); hippocampus: control (4.476 3.11), SrfGFAPCKO (378.76 8.17), striatum: control
(5.436 5.43), SrfGFAPCKO (110.86 4.94). G, Cortex, control (8.226 4.11), SrfGFAPCKO (475.76 67.75); hippocampus, control
(10.266 10.26), SrfGFAPCKO (531.66 31.96); striatum: control (17.306 11.98), SrfGFAPCKO (157.46 13.96; n=3–4 mice). H,
Immunostaining for the proliferation marker, phH3, in 12-month-old SrfGFAPCKO and control littermates showed no proliferating cells
even at this age. Scale bar: 200mm; *p,0.05, **p, 0.005, ***p, 0.0005, ****p, 0.0001. Two tailed t test. Data are mean 6 SEM.
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Figure 7. Microglial activation is seen along with astrogliosis in SrfGFAPCKO mice. A, Immunostaining for the microglia marker, Iba1,
showed increased Iba1 expression in the neocortex and hippocampus of mutant mice as compared with the control littermates,
suggesting activated microglia in mutant brain. B, Relative fluorescence intensity of Iba1 in the neocortex of Srf mutant mice com-
pared with control littermates in A shows a significant increase in Iba1 expression in the Srf mutants indicative of microgliosis.
Control (1.06 0.0), SrfGFAPCKO (1.976 0.19; n=3 mice). C, Quantification of Iba11 cells in three-week-old control and mutant mice.
Cortex, control (29.086 0.43), SrfGFAPCKO (34.46 2.68); hippocampus (Hpc), control (28.646 0.82), SrfGFAPCKO (33.806 1.40);
striatum, control (29.466 1.20), SrfGFAPCKO (32.06 0.42; n=3 mice). D, Representative images of sections immunostained for mi-
croglial marker Iba1 in aged mice (three- and 12-month-old) in SrfGFAPCKO and control littermates show increased expression of
Iba1 in the Srf mutants. Shown here is neocortex. E, Relative fluorescence intensity of Iba1 in the neocortex of Srf mutant mice
compared with control littermates shows persistent microgliosis in the Srf mutants throughout adulthood. Three months, control
(1.06 0.0), SrfGFAPCKO (1.86 0.22); 12 months, control (1.06 0.0), SrfGFAPCKO (1.716 0.17; n=3 mice). F, G, Quantification of
Iba11 cells at three months (F), cortex, control (30.006 0.62), SrfGFAPCKO (54.506 6.87); hippocampus (Hpc), control
(24.006 4.25), SrfGFAPCKO (58.756 9.00); striatum, control (29.256 1.25), SrfGFAPCKO (32.756 3.00); and 12 months (G) cortex,
control (28.256 0.57), SrfGFAPCKO (38.756 2.49); hippocampus, (Hpc), control (27.586 1.55), SrfGFAPCKO (36.7566.00); striatum,
control (28.176 0.88), SrfGFAPCKO (28.586 1.17; n=3 mice). Scale bars: 200 mm; **p, 0.005; ns, not significant. Two tailed t test.
Data are mean 6 SEM.
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Figure 8. Prolonged gliosis in SrfGFAPCKO mice does not affect neuronal survival. A, Quantitative real-time PCR for A1, A2, pan-reactive
astrocyte markers and neuroinflammatory genes shows expression of a greater number of A2 reactive genes in the brains of Srf mutant
mice compared with A1 genes. The mutant astrocytes also exhibited a higher expression of neuroinflammatory genes, Il1b and Ccl2/
Mcp-1 but not TNFa. Control (1.06 0.0), SrfGFAPCKO, Cd109 (3.4960.62), Clcf1 (2.516 0.52), Cd14 (2.826 0.51), Ptgs2 (0.906 0.25),
Psmb8 (7.436 0.83), H2T23 (2.206 0.78), H2D1 (2.46 0.65), Srgn (1.786 0.39), Serpina3n (10.886 1.86), Gfap (9.626 0.84), Il1b
(1.8066 0.16), Ccl2/Mcp-1 (13.526 1.967), TNFa (3.356 0.97; n=3 mice). B, Representative images of immunostaining for the neuronal
marker, NeuN shows normal structural integrity in three- to five-week-old SrfGFAPCKO mice compared with control littermates. C, D,
Quantification of NeuN1 cells in three- to five-week-old (C) and 12-month-old (D) control and mutant mice shows no significant change
in neuronal numbers in the mutant mice. C, Cortex, control (209.56 12.10), SrfGFAPCKO (195.26 11.18); CA1, control (78.256 16.48),
SrfGFAPCKO (148.46 34.10); CA3, control (124.46 24.47), SrfGFAPCKO (133.56 37.20); striatum, control (220.86 5.90), SrfGFAPCKO
(205.86 19.59; n=3 mice). D, Cortex, control (208.46 9.87), SrfGFAPCKO (190.06 9.71); CA1, control (119.06 22.36), SrfGFAPCKO
(148.26 12.23); CA3, control (101.06 22.05), SrfGFAPCKO (127.86 12.19); striatum, control (211.16 5.14), SrfGFAPCKO (182.16 51.89;
n=3 mice), Scale bar, 1 mm; *p, 0.05, **p, 0.005, ***p, 0.0005; ns, not significant. Two tailed t test. Data are mean 6 SEM.
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expression of a dominant negative FGFR3 (dnFGFR3) and
a constitutively active FGFR3 (caFGFR3) in astrocytes
produced different results. While caFGFR3 suppressed
astrogliosis in one study, it resulted in enlarged astrocytes
with increased branching in another (K. Kang et al., 2014;
W. Kang et al., 2014). Furthermore, expression of a
dnFGFR3 suppressed GFAP expression and hypertrophic
morphology (K. Kang et al., 2014). Nevertheless, these
observations suggest an important role for FGF signaling
in regulating the reactive state of forebrain astrocytes.
Since reactive astrocytes can either be beneficial or detri-
mental to normal functioning of the nervous system, this
process is expected to be tightly regulated to maintain as-
trocytes in a non-reactive state.
Reactive astrocytes are induced or regulated by several
extracellular signals including cytokines, growth factors,
endothelin, purines, and lipopolysaccharide (LPS), and
these factors are released by neural and non-neural cells
in the CNS following neuronal injury or in response to in-
fection (Kang and Hébert, 2011; Sofroniew, 2014). In the
SrfGFAPCKO mice, we did not observe any cell death when
analyzed at twoweeks of age (Fig. 4A–C); and therefore, cell
death is unlikely to be the cause of gliosis, which was first
observed starting at threeweeks of age. Furthermore, there
were no discernible deficits observed in BBB permeability
indicating that reactive astrocytes in the Srfmutant mice are
not induced by a leaky BBB (Fig. 5).
Depending on the severity of neural injury, astrogliosis
can manifest as mild, moderate, or severe without or with
scar formation (Pekny and Pekna, 2014; Sofroniew, 2014).
During mild and moderate astrogliosis, astrocytes exhibit hy-
pertrophy, do not proliferate and return to non-reactive state
once the underlying cause is resolved (Pekny and Pekna,
2014; Sofroniew, 2014). In severe astrogliosis, astrocytes ex-
hibit proliferation and can also result in scar formation with
significant tissue rearrangement. In the SrfGFAPCKO, the as-
trocytes exhibited hypertrophy but were not proliferative
when assessed in young and oldmice (Figs. 4D, 6H). The ab-
sence of proliferative hypertrophic reactive astrocytes has
been reported in mutant mice carrying astrocyte-specific de-
letion of genes such as Shh (Garcia et al., 2010); b 1-integrin
(Robel et al., 2009) and FGFR (Kang et al., 2014).
Furthermore, the astrogliosis in these mutant mice was
found to be restricted to specific regions in the brain likely re-
flective of their requirement in specific astrocyte populations.
In contrast, in the Srf knock-out mice, we observed wide-
spread astrogliosis in all regions of the brain including white
matter astrocytes (Fig. 6A–G). This suggests that conditional
Srf ablation in astrocytes results in conversion to reactive as-
trocytes regardless of their regional heterogeniety (Zhang
and Barres, 2010).
The Srf mutant mice also exhibited reactive microglia
starting around three weeks of age and persisted through-
out adulthood (Fig. 7). Reactive astrogliosis has been
shown to accompany reactive microglia and vice versa
(Frank and Wolburg, 1996; Zhang et al., 2010). Reactive
astrocytes are known to secrete cytokines, which can
cause the activation of microglia (Davalos et al., 2005).
Since there appears to be no injury or infection in
SrfGFAPCKO mice, the microglial activation is very likely to
be caused by the reactive astrocytes.
Studies have shown that depending on the kind of neu-
ronal injury or insult, reactive astrocytes can be broadly
classified as neurotoxic (A1) or neuroprotective (A2; Li et
al., 2008; Zamanian et al., 2012; Liddelow et al., 2017).
Since the SRF-deficient astrocytes exhibited hypertrophy
and enhanced GFAP and vimentin expression (Figs. 2, 3),
we looked at the expression of A1 and A2 astrocyte
markers. We found expression of more A2 marker genes
as compared with A1 genes in the brains SrfGFAPCKO
mice suggesting that SRF-deficient reactive astrocytes
are likely to be A2-type (Fig. 8A). A1 reactive astrocytes
have been shown to secrete neurotoxic factor(s) that re-
sulted in neuronal cell death in cultured neurons
(Liddelow et al., 2017). The presence of reactive microglia
suggested that the reactive astrocytes could induce mi-
crogliosis. We found an increased expression of Il1b and
Ccl2/Mcp-1 but not TNFa in brains of SrfGFAPCKO mice
(Fig. 8A). IL-1b and the chemokine, CCL2/MCP-1 have
been shown to induce reactive microglia and could be the
underlying cause for prolonged microgliosis (Selenica et
al., 2013; Liu and Quan, 2018). Since the SrfGFAPCKO
mice exhibited prolonged gliosis, we analyzed for neuro-
nal numbers and found no significant change in the num-
ber of neurons indicating that the reactive astrocytes in
the brains of these Srf mutant mice do not affect neuronal
survival (Fig. 8A–D).
In summary, we have identified SRF as a critical regula-
tor of reactive astrocytes in the mouse brain. Ablation of
Srf in astrocyte-specific manner results in persistent and
widespread astrogliosis. Since astrocytes in all brain re-
gions become reactive, it strongly suggests that SRF is
important for maintaining both white matter and gray mat-
ter astrocytes in a non-reactive state. The SRF-deficient
reactive astrocytes appear to be A2-like and the brains of
SrfGFAPCKO mice exhibited normal neuronal numbers de-
spite persistent gliosis. It is reasonable to speculate
that SRF expression needs to be downregulated for an
astrocyte to become reactive. It is also possible that
SRF-dependent transcription is likely affected in reac-
tive astrocytes observed in neurodegenerative disor-
ders. Future studies aimed at identification of SRF
target genes may provide novel insights into the mecha-
nisms regulating reactive astrogliosis and may provide po-
tential targets for astrocyte-targeted therapeutics.
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